Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma

Michael Naidoo, Leanne Jones, Benjamin Conboy, Wael Hamarneh, Darwin D'Souza, Karen Anthony, Lee Machado

Research output: Contribution to ConferencePosterpeer-review

Abstract

The Duchenne muscular dystrophy (DMD) gene is the largest known human gene spanning a genomic range over 2Mb. It encodes multiple protein products of varying size and function.

Several studies have emerged showing that muscular dystrophy mouse models are prone to develop spontaneous soft tissue sarcomas (STS).

High DMD expression has been linked to several cancers, including low-grade glioma (LGG), improving prognosis in some and worsening prognosis in others.

Although literature has previously linked the DMD gene to numerous cancers, none have considered the many gene products produced by the DMD gene.

Dp71 is a ubiquitous dystrophin protein and the predominant DMD product in the brain.
Original languageEnglish
Number of pages1
Publication statusPublished - 5 Sep 2022
EventCancer Research UK Brain Tumour Conference - London
Duration: 5 Sep 20227 Sep 2022

Conference

ConferenceCancer Research UK Brain Tumour Conference
CityLondon
Period5/09/227/09/22

Keywords

  • Duchenne muscular dystrophy
  • Dystrophin
  • Dp71
  • Glioma
  • low grade glioma
  • Brain tumour
  • Biomarker
  • Cancer

Fingerprint

Dive into the research topics of 'Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma'. Together they form a unique fingerprint.

Cite this